Background: Bare-metal stent is preferable to 1st generation drug-eluting stent in patients who need non-cardiac surgery within 12 months from coronary stenting despite restenosis. However, data are lacking regarding the safety of Endeavor^TM stent (Zotarolimus-eluting stent;ZES) which has been known to carry a lower risk of stent thrombosis due to rapid re-endothelialization. Methods: A total of 3098 consecutive patients treated with ZES since January 2006 were retrospectively analyzed in Korean 11 teaching hospitals. The primary endpoint was the 30-day major adverse cardiac events(MACE) including death, non-fatal myocardial infarction (MI) and target lesion revascularization. Results: 193 patients (6.2 %) with brief interruption of both aspirin and clopidogrel due to non-cardiac surgical procedure within 12 months following ZES implantation were identified. Four patients (2.1 %) experienced a MACE (2 patients: fatal, 2 patients: non-fatal MI with identified thrombus). The incidence of MACE was higher in the early-surgery group (within 3 months following stent implantation) than in the late-surgery group (3 months to 12 months after stent implantation)(Table).Conclusion: ZES appears to be safe and feasible in patients undergoing non-cardiac surgical procedure after 3 months following stent implantation.